Skip to main content

Salvage Prostatectomy — Reconstructive Indications

This page focuses on the reconstructive role of salvage prostatectomy in the setting of a necrotic or treatment-devastated prostate — prostatic abscess/necrosis, urorectal fistula, devastated bladder outlet, and end-stage radiation cystitis. Oncologic indications, oncologic outcomes (biochemical recurrence, cancer-specific and overall survival), and salvage-focal-vs-salvage-prostatectomy comparisons are out of scope here; this article addresses what reconstructive surgeons need to know about operating in a previously irradiated/ablated prostatic field and reconstructing the lower urinary tract afterward.

The irradiated/necrotic tissue environment profoundly impairs healing — particularly at the vesicourethral anastomosis (VUA) — making standard reconstruction unreliable and necessitating alternative reconstructive strategies.[1][2][3]

Why the Prostate Becomes Necrotic​

Prostatic necrosis is a consequence of prior ablative or radiation treatments:

  • Radiation therapy (EBRT, brachytherapy): Chronic hypoxia, fibrosis, and vascular damage lead to tissue devitalization over months to years.[1][4]
  • Cryotherapy: Coagulative necrosis from freeze-thaw cycles; prostatic abscess is a reported complication.[5]
  • HIFU: Thermal coagulative necrosis. Histologically, 72% of post-HIFU biopsies show necrosis with associated inflammation.[6][7][8]

The necrotic prostate creates a hostile surgical field: obliterated tissue planes, dense fibrosis, loss of normal anatomic landmarks, and poor tissue vascularity.[9][10]

Reconstructive Indications​

  1. Prostatic abscess / necrosis causing intractable symptoms (pain, sepsis, fistula).[5][12]
  2. Urorectal fistula secondary to prostatic necrosis/abscess.[12]
  3. Devastated bladder outlet — densely fibrotic and/or necrotic posterior urethra refractory to endoscopic management.[3]
  4. End-stage radiation cystitis with small fibrotic bladder requiring cystoprostatectomy.[13]

For reconstructive-surgery scope, this page does not cover the standard oncologic indication (biopsy-proven local recurrence) — refer to oncologic guidelines for that decision.

Surgical Challenges Specific to the Necrotic Prostate​

  • Obliterated posterior planes: The plane between prostate and rectum is fibrotic and adherent, increasing the risk of rectal injury (0.5–2% in contemporary series, historically up to 28%).[1][14][15]
  • Apical dissection difficulty: The apex is the most challenging area due to fibrosis around the external sphincter, risking sphincter damage and incontinence.[10]
  • Poor tissue quality for anastomosis: Necrotic/irradiated bladder neck and urethral tissue heals poorly, leading to high rates of anastomotic leak (14.6–35.5%) and anastomotic stricture (7.7–41%).[16][15][17][18]
  • Loss of surgical landmarks: Tissue planes that normally guide nerve-sparing and sphincter preservation are distorted or absent.[9]

Reconstructive Options​

Option 1 — Standard Vesicourethral Anastomosis (VUA)​

Used when tissue quality permits. In the salvage setting:

  • VUA disruption / leak in 35.5% with standard suturing (vs 0% in primary RP).[16]
  • Bladder neck contracture in 31% within one year — the most common late complication; often presents as VUAS.[18]
  • Continence rates significantly worse than primary RP: 16–57% pad-free at 12 months.[15][18][19][20][9]

Tissue biograft reinforcement. Incorporation of a urinary bladder extracellular matrix (UB-ECM) scaffold into the posterior VUA and distal bladder neck during salvage RARP reduced VUA disruption from 35.5% to 6.7% (p = 0.045) and decreased catheterization time from 17.4 to 11.2 days.[16]

Option 2 — Bladder Neck Closure + Continent Catheterizable Stoma + Bladder Augmentation (MD Anderson)​

Developed by Pisters et al. specifically for salvage prostatectomy patients with preexisting voiding symptoms or when VUA is not feasible due to tissue necrosis:[21][22][23]

  • The prostate is removed and the bladder neck is completely closed rather than anastomosed to the urethra. See Bladder Neck Closure.
  • Augmentation cystoplasty with ileum to increase capacity of the irradiated bladder.
  • Continent catheterizable channel (appendicovesicostomy or Monti ileovesicostomy) for emptying.
  • Rectus abdominis muscle flap interposed in the pelvis to provide well-vascularized tissue, promote healing, and reduce fistula risk.[2]

Long-term outcomes (mean 61 months): 83% continence rate, significantly superior to standard VUA in the salvage setting. Stomal revision required in 33%; 86% would choose the surgery again.[23] This approach effectively eliminates the problem of anastomotic stricture and sphincteric incontinence by bypassing the damaged urethra entirely.[21][22]

Option 3 — Salvage Cystoprostatectomy + Urinary Diversion​

Indicated when the bladder is also severely damaged (radiation cystitis, small fibrotic bladder, end-stage bladder) or when the devastated outlet precludes reconstruction:[13][24][25]

Option 4 — Total Lower Urinary Tract Reconstruction (Patil/Boyd)​

For patients with a defunctionalized bladder and recalcitrant posterior urethral stenosis (often post-radiation), a novel approach combines salvage cystectomy, orthotopic ileal neobladder, and urethral pull-through, followed by staged AUS placement. All 8 patients maintained functional urinary storage and urethral patency at a median of 58 months, avoiding cutaneous diversion.[26]

Option 5 — Salvage Prostatectomy as a Component of Fistula Repair​

When prostatic necrosis/abscess results in urorectal fistula, salvage prostatectomy serves as a key component of fistula repair by removing the necrotic tissue and allowing interposition of well-vascularized tissue (tunica vaginalis flap, peritoneal flap, omental flap, or rectus flap) between the urinary and rectal tracts.[12][27]

Adjunctive Reconstructive Techniques​

  • Rectus abdominis muscle flap: Interposed in the pelvis to fill dead space, provide vascularized tissue, and reduce fistula/abscess risk. A key innovation in salvage surgery.[2]
  • Omental pedicle flap: Alternative vascularized tissue interposition.
  • UB-ECM scaffold: Reduces VUA leak rates from 35.5% to 6.7%.[16]
  • Bladder-neck tubularization: Narrows the bladder neck to improve continence when tissue quality is marginal.

Reconstructive Outcomes by Approach​

ApproachContinenceKey Reconstructive ComplicationsBest Candidates
Standard VUA (open)16–39%BNC 31%, stricture 17%, leak 35%Minimal tissue necrosis, good sphincter
Standard VUA (robotic)57–67%BNC 8%, leak 15%, stricture 8%Moderate tissue damage, experienced surgeon
VUA + UB-ECM scaffold~57%Leak 6.7% (vs 35.5% without)Moderate necrosis, salvage RARP
BN closure + cath stoma + augmentation73–83%Stomal revision 27–33%, serious complications 31%Severe necrosis, preexisting voiding symptoms
Cystoprostatectomy + neobladder67% day / 56% nightMay need AUS, ileus, pyelonephritisEnd-stage bladder + necrotic prostate
Total LUT reconstruction100% with AUSMedian 2 AUS revisionsDefunctionalized bladder + recalcitrant stenosis

References: [1][2][3][16][21][22][23][24][25][26]

Patient Selection and Counseling​

  • Multidisciplinary evaluation is essential, ideally at a high-volume center with expertise in both salvage oncologic surgery and urologic reconstruction.
  • Patients must understand that functional outcomes are substantially inferior to primary RP: continence 16–67%; potency recovery is uncommon.[9][19]
  • The reconstructive plan should be individualized based on the degree of tissue necrosis, bladder function, patient dexterity (for self-catheterization), and goals of care.
  • In patients with densely fibrotic and/or necrotic posterior urethra, failed reconstruction, or refractory incontinence, urinary diversion with or without cystectomy may be the most appropriate option.[3][32]

References​

1. Light A, Peters M, Arya M, et al. "Salvage Focal Therapy vs Radical Prostatectomy for Localized Radiorecurrent Prostate Cancer." JAMA Oncology. 2026. doi:10.1001/jamaoncol.2025.6448

2. Leibovici D, Spiess PE, Heller L, et al. "Salvage Surgery for Locally Recurrent Prostate Cancer After Radiation Therapy: Tricks of the Trade." Urologic Oncology. 2008;26(1):9-16. doi:10.1016/j.urolonc.2006.12.016

3. Martins FE, Holm HV, Lumen N. "Devastated Bladder Outlet in Pelvic Cancer Survivors: Issues on Surgical Reconstruction and Quality of Life." Journal of Clinical Medicine. 2021;10(21):4920. doi:10.3390/jcm10214920

4. Martin JM, Richardson M, Siva S, et al. "Mechanisms, Mitigation, and Management of Urinary Toxicity From Prostate Radiotherapy." The Lancet Oncology. 2022;23(12):e534-e543. doi:10.1016/S1470-2045(22)00544-7

5. Wu I, Jones JS. "Intraprostatic Abscess as a Complication of Salvage Cryotherapy." Urology. 2010;76(4):848. doi:10.1016/j.urology.2009.09.063

6. Collins K, Brocken E, Bahler CD, et al. "High-Intensity Focused Ultrasound for the Treatment of Prostate Cancer: Assessing Location of Failure After Focal Therapy in Prostate Cancer and Review of Histological Characteristics and Clinicopathologic Correlates After Treatment — A 5-Year Experience." Human Pathology. 2022;119:79-84. doi:10.1016/j.humpath.2021.11.005

7. Biermann K, Montironi R, Lopez-Beltran A, Zhang S, Cheng L. "Histopathological Findings After Treatment of Prostate Cancer Using High-Intensity Focused Ultrasound (HIFU)." The Prostate. 2010;70(11):1196-200. doi:10.1002/pros.21154

8. Ghafoor S, Becker AS, Stocker D, et al. "Magnetic Resonance Imaging of the Prostate After Focal Therapy With High-Intensity Focused Ultrasound." Abdominal Radiology. 2020;45(11):3882-3895. doi:10.1007/s00261-020-02577-5

9. Covas Moschovas M, Saikali S, Sandri M, et al. "Outcomes of Salvage Robotic-Assisted Radical Prostatectomy: High-Volume Multicentric Data From the European Association of Urology Robotic Urology Section Scientific Working Group." European Urology. 2025;88(1):103-113. doi:10.1016/j.eururo.2025.03.009

10. Calleris G, Marra G, Dalmasso E, et al. "Is It Worth to Perform Salvage Radical Prostatectomy for Radio-Recurrent Prostate Cancer? A Literature Review." World Journal of Urology. 2019;37(8):1469-1483. doi:10.1007/s00345-019-02749-z

12. Gözen AS, Malkoc E, Al-Sudani I, Rassweiler J. "Laparoscopic Urorectal Fistula Repair: Value of the Salvage Prostatectomy and Review of Current Approaches." Journal of Endourology. 2012;26(9):1171-6. doi:10.1089/end.2012.0024

13. Shekarriz B, Upadhyay J, Pontes JE. "Salvage Radical Prostatectomy." The Urologic Clinics of North America. 2001;28(3):545-53. doi:10.1016/s0094-0143(05)70162-2

14. Chade DC, Eastham J, Graefen M, et al. "Cancer Control and Functional Outcomes of Salvage Radical Prostatectomy for Radiation-Recurrent Prostate Cancer: A Systematic Review of the Literature." European Urology. 2012;61(5):961-71. doi:10.1016/j.eururo.2012.01.022

15. Gontero P, Marra G, Alessio P, et al. "Salvage Radical Prostatectomy for Recurrent Prostate Cancer: Morbidity and Functional Outcomes From a Large Multicenter Series of Open Versus Robotic Approaches." The Journal of Urology. 2019;202(4):725-731. doi:10.1097/JU.0000000000000327

16. Ogaya-Pinies G, Kadakia Y, Palayapalayam-Ganapathi H, et al. "Use of Scaffolding Tissue Biografts to Bolster Vesicourethral Anastomosis During Salvage Robot-Assisted Prostatectomy Reduces Leak Rates and Catheter Times." European Urology. 2018;74(1):92-98. doi:10.1016/j.eururo.2016.10.004

17. Gotto GT, Yunis LH, Vora K, et al. "Impact of Prior Prostate Radiation on Complications After Radical Prostatectomy." The Journal of Urology. 2010;184(1):136-42. doi:10.1016/j.juro.2010.03.031

18. Perera M, Vilaseca A, Tin AL, et al. "Morbidity of Salvage Radical Prostatectomy: Limited Impact of the Minimally Invasive Approach." World Journal of Urology. 2022;40(7):1637-1644. doi:10.1007/s00345-022-04031-1

19. Drobner J, Kaldany A, Shah MS, Ghodoussipour S. "The Role of Salvage Radical Prostatectomy in Patients With Radiation-Resistant Prostate Cancer." Cancers. 2023;15(14):3734. doi:10.3390/cancers15143734

20. Ogaya-Pinies G, Linares-Espinos E, Hernandez-Cardona E, et al. "Salvage Robotic-Assisted Radical Prostatectomy: Oncologic and Functional Outcomes From Two High-Volume Institutions." World Journal of Urology. 2019;37(8):1499-1505. doi:10.1007/s00345-018-2406-4

21. Pisters LL, English SF, Scott SM, et al. "Salvage Prostatectomy With Continent Catheterizable Urinary Reconstruction: A Novel Approach to Recurrent Prostate Cancer After Radiation Therapy." The Journal of Urology. 2000;163(6):1771-4. doi:10.1016/s0022-5347(05)67539-8

22. De E, Pisters LL, Pettaway CA, Scott S, Westney OL. "Salvage Prostatectomy With Bladder Neck Closure, Continent Catheterizable Stoma and Bladder Augmentation: Feasibility and Patient Reported Continence Outcomes at 32 Months." The Journal of Urology. 2007;177(6):2200-4. doi:10.1016/j.juro.2007.01.151

23. Zafirakis H, De EJ, Pisters LL, Pettaway C, Westney OL. "Long-Term Outcomes and Patient Satisfaction of Continent Catheterizable Limb and Augmentation Cystoplasty Simultaneous With Salvage Prostatectomy." Neurourology and Urodynamics. 2010;29 Suppl 1:S51-6. doi:10.1002/nau.20898

24. Bochner BH, Figueroa AJ, Skinner EC, et al. "Salvage Radical Cystoprostatectomy and Orthotopic Urinary Diversion Following Radiation Failure." The Journal of Urology. 1998;160(1):29-33.

25. Gheiler EL, Wood DP, Montie JE, Pontes JE. "Orthotopic Urinary Diversion Is a Viable Option in Patients Undergoing Salvage Cystoprostatectomy for Recurrent Prostate Cancer After Definitive Radiation Therapy." Urology. 1997;50(4):580-4. doi:10.1016/S0090-4295(97)00264-1

26. Patil MB, Hannoun D, Reyblat P, Boyd SD. "Total Bladder and Posterior Urethral Reconstruction: Salvage Technique for Defunctionalized Bladder With Recalcitrant Posterior Urethral Stenosis." The Journal of Urology. 2015;193(5):1649-54. doi:10.1016/j.juro.2014.11.102

27. Ullrich NF, Wessells H. "A Technique of Bladder Neck Closure Combining Prostatectomy and Intestinal Interposition for Unsalvageable Urethral Disease." The Journal of Urology. 2002;167(2 Pt 1):634-6. doi:10.1016/S0022-5347(01)69101-8

32. Faris SF, Milam DF, Dmochowski RR, Kaufman MR. "Urinary Diversions After Radiation for Prostate Cancer: Indications and Treatment." Urology. 2014;84(3):702-6. doi:10.1016/j.urology.2014.04.023